INVESTOR DEADLINE: Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - The Soleno Therapeutics, Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims centered around undisclosed safety concerns related to its only commercial product, DCCR, for treating hyperphagia in Prader-Willi syndrome patients [1][3]. Company Overview - Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its primary product being diazoxide choline extended-release tablets (DCCR) [2]. Allegations of the Lawsuit - The lawsuit alleges that Soleno and its executives failed to disclose significant safety concerns related to DCCR, including issues of excess fluid retention in clinical trial participants [3]. - It is claimed that the administration of DCCR posed materially greater safety risks than disclosed, leading to lower commercial viability and undisclosed risks of adverse events post-launch [3]. - The lawsuit cites a critical report by Scorpion Capital LLC that negatively impacted Soleno's stock price, leading to a nearly 12% decline over two trading days [4]. Impact on Stock Price - Following the report by Scorpion Capital, Soleno's stock price dropped approximately 19% after a patient death was reported related to DCCR [5]. - On November 4, 2025, Soleno reported a disruption in DCCR's launch trajectory, resulting in a further 27% decline in stock price due to concerns raised within the Prader-Willi syndrome community [6]. Legal Process - Investors who purchased Soleno common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, which allows them to act on behalf of all class members [7]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery from the lawsuit [8]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm representing investors in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [9].